Category

0
5
Emergency Medicine Literature of Note: FFP Vs. PCCs for Warfarin Reversal – Special Advertising Supplement
emlitofnote.com
about 7 years ago

2
40
Risk of GI bleeding associated with oral anticoagulants
Determining the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of GI bleeding.
bmj.com
about 7 years ago

0
17
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.
feeds.bmj.com
about 7 years ago

0
13
Safety of new oral anticoagulants
Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.
feeds.bmj.com
about 7 years ago

0
15
Safety of new oral anticoagulants
Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.
feeds.bmj.com
about 7 years ago
0
24
Safety of new oral anticoagulants
Two linked papers (doi:10.1136/bmj.h1857, doi:10.1136/bmj.h1585) report additional evidence on the risks of gastrointestinal bleeding among patients taking the novel oral anticoagulants dabigatran and rivaroxaban.1 2 From a database of more than 100 million US adults, Abraham and colleagues identified almost 220 000 new users of dabigatran, rivaroxaban, or warfarin between November 2010 and September 2013.1 In their comparison of propensity score matched patients, the risk of gastrointestinal bleeding increased significantly with age for both new oral anticoagulants, relative to warfarin. By age 75, the risk of gastrointestinal bleeding associated with rivaroxaban exceeded that with warfarin, for patients with or without atrial fibrillation. Among patients taking dabigatran, the association between older age and higher risk was confined to those with atrial fibrillation, although the data included very few patients without atrial fibrillation taking this drug.
feeds.bmj.com
about 7 years ago
0
6
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study
Objectives To determine the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of gastrointestinal bleeding.
feeds.bmj.com
about 7 years ago
0
14
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.
feeds.bmj.com
about 7 years ago

0
4
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study
Objectives To determine the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of gastrointestinal bleeding.
feeds.bmj.com
about 7 years ago
0
6
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.
feeds.bmj.com
about 7 years ago

1
14
Warfarin Side Effects in Detail - Drugs.com
Learn about the potential side effects of warfarin. Includes common and rare side effects information for consumers and healthcare professionals.
drugs.com
about 7 years ago
0
7
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
Objective To determine the real world risk of gastrointestinal bleeding associated with the use of the novel oral anticoagulants dabigatran and rivaroxaban compared with warfarin.
feeds.bmj.com
about 7 years ago